Back to Journals » Research Reports in Clinical Cardiology » Volume 10

Spotlight on sudden arrhythmic death syndrome

Authors Yuan D, Raju H

Received 25 June 2019

Accepted for publication 27 August 2019

Published 12 September 2019 Volume 2019:10 Pages 57—66

DOI https://doi.org/10.2147/RRCC.S187480

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Richard Kones


David Yuan,1 Hariharan Raju1,2

1Cardiology Department, Concord Repatriation General Hospital, Sydney, Australia; 2Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia

Correspondence: Hariharan Raju
Cardiology Department, Concord Repatriation General Hospital, Hospital Road, Concord West 2139, Australia
Tel +61 29 812 2900
Fax +61 29 475 1155
Email hari.raju@mqhealth.org.au

Abstract: Sudden cardiac death (SCD) is defined as death from a cardiac cause within 1 hr of symptom onset or, if unwitnessed, in a person last seen well within 24 hrs. Sudden arrhythmic death syndrome (SADS) describes cases of SCD with no abnormalities found on expert autopsy attributable as the cause of death. The epidemiology of these conditions has been challenging to study as definitions have changed over time; however, it is apparent that the incidence of SCD increases with age whilst SADS decreases as coronary artery disease becomes more prevalent. Accurate reporting of truly negative autopsies of SCDs has been assisted by guidelines from governing bodies such as The Association for European Cardiovascular Pathology, allowing identification of SADS cases. Primary arrhythmic cardiac conditions like ong QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia are the predominant etiologies of SADS. When the decedent did not have a known phenotype for these conditions, clinical evaluation using screening tests like echocardiogram, resting and stress electrocardiograms and holter monitoring, followed by specialized testing when appropriate such as cardiac magnetic resonance and pharmacological provocation testing of surviving family members becomes crucial in potentially identifying the cause and guide targeted genetic testing. Although advancement in gene analysis such as next-generation sequencing has also allowed the application of “molecular autopsy” to identify pathogenic variants to establish the cause of death and enable cascade testing and risk stratification of family members, many of the genetic variants identified through this method have been classified as non-pathogenic since the establishment of standards and guidelines by the American College of Medical Genetics. Whilst majority of cases of SADS are still unexplained, there is increasing awareness and understanding of this syndrome allowing appropriate identification of surviving family members at risk and implementation of measures to prevent further premature death.

Keywords: sudden cardiac death, sudden arrhythmic death syndrome, sudden unexplained death, unexplained cardiac death, molecular autopsy
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]